Cite
HARVARD Citation
Quintela-Fandino, M. et al. (n.d.). 72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers. Annals of oncology. p. . [Online].